Acute Myeloid Leukemia Research Today is a free monthly online journal that collates and summarizes the latest research about Acute Myeloid Leukemia, including details on aml, symptoms, treatment, information.

The INV(16) cooperates with ARF haploinsuffiency to induce acute myeloid leukemia.

Moreno-Miralles I, Pan L, Keates-Baleeiro J, Durst-Goodwin K, Yang C, Kim HG, Thompson MA, Klug CA, Cleveland JL, Hiebert SW

Biochemistry Dept., Vanderbilt Univ. School of Medicine, Nashville, TN 37232.

The inv(16) is one of the most frequent chromosomal translocations associated with acute myeloid leukemia and creates a chimeric fusion protein consisting of most of the RUNX1 co-factor core binding factor beta (CBFss) fused to the smooth muscle myosin heavy chain MYH11. Expression of the ARF tumor suppressor is regulated by RUNX1, suggesting that the inv(16) fusion protein (IFP) may repress ARF expression. We established a murine bone marrow transplant model of the inv(16) in which wild type, Arf +/- and Arf -/- bone marrow were engineered to express the IFP. IFP expression was sufficient to induce a myelomonocytic AML even when expressed in wild type bone marrow, yet removal of only a single allele of Arf greatly accelerated the disease, indicating that Arf is haploinsufficent for the induction of AML in the presence of the inv(16).

Published 3 October 2005 in J Biol Chem.
Full-text of this article is available online (may require subscription).

© 2004-2008 Acute Myeloid Leukemia Research Today. All Rights Reserved.